Abeona Therapeutics shares are trading higher after the company announced the FDA accepted and granted Priority Review for the Biologics License Application for pz-cel.
Portfolio Pulse from Benzinga Newsdesk
Abeona Therapeutics' stock is trading higher following the announcement that the FDA has accepted and granted Priority Review for their Biologics License Application for pz-cel.
November 27, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abeona Therapeutics' stock price is likely to experience a positive impact in the short term due to the FDA's acceptance and Priority Review status for their Biologics License Application for pz-cel.
The FDA's acceptance and Priority Review of a Biologics License Application is a significant positive development for a biotech company. It suggests a faster review process and a higher likelihood of approval, which can lead to increased investor confidence and a rise in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100